Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free NAMSW Stock Alerts

NewAmsterdam Pharma (NAMSW) Financials

NewAmsterdam Pharma logo
$27.31 -2.68 (-8.94%)
As of 05/14/2026 03:30 PM Eastern
Compare
Annual Income Statements for NewAmsterdam Pharma

Annual Income Statements for NewAmsterdam Pharma

This table shows NewAmsterdam Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.02 -32 -30 -177 -242 -204
Consolidated Net Income / (Loss)		 -7.02 -32 -23 -177 -242 -204
Net Income / (Loss) Continuing Operations		 -7.02 -32 -30 -177 -242 -204
Total Pre-Tax Income 		-7.02 -32 -23 -177 -242 -204
Total Operating Income		 -6.63 -34 -3.56 -183 -176 -226
Total Gross Profit		 0.00 0.01 103 14 46 23
Total Revenue		 0.00 0.01 103 14 46 23
Operating Revenue		 0.00 0.01 103 14 46 23
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 6.63 34 106 197 222 248
Selling, General & Admin Expense		 1.69 5.44 20 38 70 106
Research & Development Expense		 4.94 28 87 159 151 142
Total Other Income / (Expense), net		 -0.42 1.39 -27 6.06 -65 22
Interest Expense		 0.42 0.24 0.29 0.00 0.00 0.00
Interest & Investment Income		 0.00 - 0.00 11 17 28
Other Income / (Expense), net		 - 1.63 -27 -5.23 -82 -5.73
Income Tax Expense		 0.00 0.00 0.00 0.03 -0.00 0.00
Basic Earnings per Share		 ($0.76) - ($1.19) ($2.15) ($2.56) ($1.72)
Weighted Average Basic Shares Outstanding		 - - 81.56M 89.27M 109.82M 114.98M
Diluted Earnings per Share		 ($0.76) ($1.37) ($1.19) ($2.15) ($2.56) ($1.72)
Weighted Average Diluted Shares Outstanding		 - - 81.56M 89.27M 109.82M 114.98M
Weighted Average Basic & Diluted Shares Outstanding		 - - 81.56M 89.27M 109.82M 114.98M

Quarterly Income Statements for NewAmsterdam Pharma

This table shows NewAmsterdam Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -47 -49 -94 -39 -17 -92 -40 -17 -72 -75 -48
Consolidated Net Income / (Loss)		 -47 -49 -94 -39 -17 -92 -40 -17 -72 -75 -48
Net Income / (Loss) Continuing Operations		 -47 -49 -94 -39 -17 -92 -40 -17 -72 -75 -48
Total Pre-Tax Income 		-47 -49 -94 -39 -17 -92 -40 -17 -72 -75 -48
Total Operating Income		 -50 -51 -55 -53 -25 -43 -69 -36 -55 -66 -58
Total Gross Profit		 2.94 0.80 1.40 2.28 29 13 2.98 19 0.35 0.03 3.04
Total Revenue		 2.94 0.80 1.40 2.28 29 13 2.98 19 0.35 0.03 3.04
Operating Revenue		 2.94 0.80 1.40 2.28 29 13 2.98 19 0.35 0.03 3.04
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 52 52 57 55 54 56 72 55 55 66 61
Selling, General & Admin Expense		 9.13 11 14 16 18 21 27 27 25 27 23
Research & Development Expense		 43 41 42 38 36 35 45 28 31 39 38
Total Other Income / (Expense), net		 2.43 1.61 -38 14 8.36 -49 29 18 -17 -8.94 9.98
Interest & Investment Income		 3.06 2.67 3.08 4.87 4.44 4.49 7.35 7.06 6.71 6.47 5.65
Other Income / (Expense), net		 -0.63 -1.06 -41 8.70 3.91 -53 22 11 -24 -15 4.33
Income Tax Expense		 0.00 0.03 0.00 0.00 -0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.57) ($0.60) ($1.06) ($0.41) ($0.18) ($0.91) ($0.34) ($0.15) ($0.61) ($0.62) ($0.40)
Weighted Average Basic Shares Outstanding		 - 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M 112.63M 113.39M 114.98M 116.90M
Diluted Earnings per Share		 ($0.57) ($0.60) ($1.06) ($0.41) ($0.18) ($0.91) ($0.34) ($0.15) ($0.61) ($0.62) ($0.40)
Weighted Average Diluted Shares Outstanding		 - 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M 112.63M 113.39M 114.98M 116.90M
Weighted Average Basic & Diluted Shares Outstanding		 - 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M 112.63M 113.39M 114.98M 116.90M

Annual Cash Flow Statements for NewAmsterdam Pharma

This table details how cash moves in and out of NewAmsterdam Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.52 50 402 -132 438 -293
Net Cash From Operating Activities		 -7.28 -28 11 -141 -159 -148
Net Cash From Continuing Operating Activities		 -7.28 -28 11 -141 -159 -148
Net Income / (Loss) Continuing Operations		 -7.02 -32 -23 -177 -242 -204
Consolidated Net Income / (Loss)		 -7.02 -32 -23 -177 -242 -204
Depreciation Expense		 0.00 0.02 0.01 0.05 0.11 0.22
Amortization Expense		 - - 0.00 0.00 -0.23 -1.41
Non-Cash Adjustments To Reconcile Net Income		 0.39 -0.45 23 34 98 52
Changes in Operating Assets and Liabilities, net		 -0.65 4.32 10 1.84 -15 5.34
Net Cash From Investing Activities		 0.00 -0.02 -0.22 -0.02 -63 -175
Net Cash From Continuing Investing Activities		 0.00 -0.02 -0.22 -0.02 -63 -175
Purchase of Property, Plant & Equipment		 - -0.02 -0.22 -0.02 -0.67 -0.25
Purchase of Investments		 - - 0.00 0.00 -62 -297
Sale and/or Maturity of Investments		 - - - 0.00 0.00 122
Net Cash From Financing Activities		 14 78 392 8.91 660 30
Net Cash From Continuing Financing Activities		 14 78 392 8.91 660 30
Repurchase of Common Equity		 - 0.00 0.00 0.00 -0.54 -1.59
Other Financing Activities, net		 - - -5.05 8.91 660 31
Cash Income Taxes Paid		 - - 0.00 0.03 0.00 0.00

Quarterly Cash Flow Statements for NewAmsterdam Pharma

This table details how cash moves in and out of NewAmsterdam Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -47 -33 143 -50 -13 357 -27 -193 -24 -48 -31
Net Cash From Operating Activities		 -47 -33 -55 -54 -13 -37 -36 -38 -33 -41 -31
Net Cash From Continuing Operating Activities		 -47 -33 -55 -54 -13 -37 -36 -38 -33 -41 -31
Net Income / (Loss) Continuing Operations		 -47 -49 -94 -39 -17 -92 -40 -17 -72 -75 -48
Consolidated Net Income / (Loss)		 -47 -49 -94 -39 -17 -92 -40 -17 -72 -75 -48
Depreciation Expense		 0.01 0.01 0.02 0.02 0.03 0.05 0.05 0.05 0.06 0.06 0.06
Amortization Expense		 - - 0.00 - - - -0.51 -0.47 -0.40 -0.02 0.01
Non-Cash Adjustments To Reconcile Net Income		 2.98 6.08 50 -9.64 3.60 72 9.20 -18 41 19 29
Changes in Operating Assets and Liabilities, net		 -2.84 10 -11 -5.35 0.52 -17 -5.68 -1.98 -1.63 15 -11
Net Cash From Investing Activities		 -0.01 -0.00 -0.39 -0.21 -0.08 -62 2.86 -159 2.51 -21 -12
Net Cash From Continuing Investing Activities		 -0.01 -0.00 -0.39 -0.21 -0.08 -62 2.86 -159 2.51 -21 -12
Purchase of Property, Plant & Equipment		 -0.01 -0.00 -0.39 -0.21 -0.08 -0.00 -0.02 -0.09 -0.04 -0.10 -0.04
Purchase of Investments		 - - 0.00 - - - -9.63 -184 -32 -72 -62
Sale and/or Maturity of Investments		 - - 0.00 - - - 13 25 34 51 51
Net Cash From Financing Activities		 0.19 - 198 4.66 0.06 457 6.52 3.43 5.89 14 11
Net Cash From Continuing Financing Activities		 0.19 - 198 4.66 0.06 457 6.52 3.43 5.89 14 11
Repurchase of Common Equity		 - - -0.52 - - -0.03 -1.59 - - - 0.00
Other Financing Activities, net		 0.19 - 199 4.66 0.06 457 8.11 3.43 5.89 14 11

Annual Balance Sheets for NewAmsterdam Pharma

This table presents NewAmsterdam Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 68 569 347 865 769
Total Current Assets		 67 479 347 863 676
Cash & Equivalents		 60 469 340 772 490
Restricted Cash		 - - - 0.00 1.32
Short-Term Investments		 - - 0.00 62 146
Prepaid Expenses		 0.00 0.16 6.34 24 38
Other Current Assets		 - - 0.00 4.95 0.00
Plant, Property, & Equipment, net		 0.22 0.15 0.05 0.24 0.38
Total Noncurrent Assets		 0.81 89 0.26 0.97 93
Long-Term Investments		 - - - 0.00 93
Goodwill		 - - 0.17 0.53 0.41
Other Noncurrent Operating Assets		 - - 0.09 0.43 0.19
Total Liabilities & Shareholders' Equity		 68 569 347 865 769
Total Liabilities		 11 50 59 107 86
Total Current Liabilities		 11 38 50 107 86
Accounts Payable		 11 20 28 18 24
Current Deferred Revenue		 0.00 14 8.94 6.01 3.99
Other Current Liabilities		 0.06 0.07 13 83 57
Total Noncurrent Liabilities		 0.13 12 8.81 0.20 0.07
Noncurrent Deferred Revenue		 0.00 4.81 1.02 - 0.00
Other Noncurrent Operating Liabilities		 0.00 12 7.79 0.20 0.07
Commitments & Contingencies		 - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 56 518 288 758 683
Total Preferred & Common Equity		 56 518 288 758 683
Total Common Equity		 56 518 288 758 683
Common Stock		 95 641 601 1,312 1,441
Retained Earnings		 - - -317 -559 -762
Accumulated Other Comprehensive Income / (Loss)		 -39 -128 4.42 4.47 4.79

Quarterly Balance Sheets for NewAmsterdam Pharma

This table presents NewAmsterdam Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 488 447 439 818 815 786 733
Total Current Assets		 488 445 438 817 770 732 658
Cash & Equivalents		 481 431 423 748 564 538 458
Restricted Cash		 - - - - - 1.31 1.34
Short-Term Investments		 - - - 60 175 165 178
Prepaid Expenses		 6.68 15 15 8.83 31 28 21
Other Current Assets		 - - - 0.00 0.00 0.00 0.00
Plant, Property, & Equipment, net		 0.10 0.23 0.23 0.24 0.31 0.32 0.38
Total Noncurrent Assets		 0.54 1.10 1.09 0.87 45 54 74
Long-Term Investments		 - - - - 44 53 71
Goodwill		 0.49 0.54 0.59 0.50 0.47 0.44 0.38
Other Noncurrent Operating Assets		 0.05 0.56 0.49 0.37 0.31 0.25 2.61
Total Liabilities & Shareholders' Equity		 488 447 439 818 815 786 733
Total Liabilities		 77 59 60 41 37 58 67
Total Current Liabilities		 60 45 41 41 37 58 67
Accounts Payable		 19 15 18 14 15 14 13
Current Deferred Revenue		 8.12 6.06 4.50 3.03 0.00 0.00 3.99
Other Current Liabilities		 33 24 19 24 21 45 50
Total Noncurrent Liabilities		 17 14 19 0.14 0.10 0.09 0.00
Noncurrent Deferred Revenue		 0.44 0.22 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 16 14 19 0.14 0.10 0.09 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 412 387 379 777 778 728 665
Total Preferred & Common Equity		 412 387 379 777 778 728 665
Total Common Equity		 412 387 379 777 778 728 665
Common Stock		 818 833 841 1,371 1,390 1,411 1,472
Retained Earnings		 -411 -450 -466 -598 -615 -687 -811
Accumulated Other Comprehensive Income / (Loss)		 4.42 4.42 4.42 4.43 4.33 4.64 4.22

Annual Metrics And Ratios for NewAmsterdam Pharma

This table displays calculated financial ratios and metrics derived from NewAmsterdam Pharma's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 1,008,087.71% -86.28% 223.37% -50.61%
EBITDA Growth		 0.00% -384.22% 6.34% -525.62% -37.44% 10.05%
EBIT Growth		 0.00% -384.37% 6.36% -525.60% -37.35% 10.47%
NOPAT Growth		 0.00% -409.00% 89.46% -5,043.86% 3.65% -28.02%
Net Income Growth		 0.00% -360.89% 30.07% -681.73% -36.54% 15.64%
EPS Growth		 0.00% -80.82% 13.11% -80.67% -19.07% 32.81%
Operating Cash Flow Growth		 0.00% -291.24% 137.45% -1,424.13% -12.28% 6.80%
Free Cash Flow Firm Growth		 0.00% 0.00% -176.58% 51.69% -269.23% -90.27%
Invested Capital Growth		 0.00% 0.00% 1,464.64% -205.66% -47.32% 39.05%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 35.63% -36.15%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -20.91% 6.24%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -20.81% 6.19%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 4.26% -11.21%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -21.46% 7.80%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -13.78% 14.43%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -2.86% -2.35%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -19.97%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -74.82% -59.66%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -315,217.31% -29.28% -1,335.30% -567.55% -1,033.62%
Operating Margin		 0.00% -331,406.51% -3.46% -1,298.56% -386.91% -1,002.90%
EBIT Margin		 0.00% -315,372.86% -29.29% -1,335.65% -567.30% -1,028.36%
Profit (Net Income) Margin		 0.00% -317,772.91% -22.04% -1,255.76% -530.25% -905.74%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.02% 100.00% 100.00%
Interest Burden Percent		 105.89% 100.76% 75.24% 94.00% 93.47% 88.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -10.91% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -3.29% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 3.03% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -57.44% -7.88% -43.87% -46.20% -28.29%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -112.38% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -47.48% -9.45% -41.10% -42.66% -28.33%
Return on Assets (ROA)		 0.00% -47.84% -7.11% -38.64% -39.88% -24.95%
Return on Common Equity (ROCE)		 0.00% -57.44% -7.88% -43.87% -46.20% -28.29%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -57.44% -4.37% -61.35% -31.89% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.64 -24 -2.49 -128 -123 -158
NOPAT Margin		 0.00% -231,984.56% -2.42% -908.99% -270.84% -702.03%
Net Nonoperating Expense Percent (NNEP)		 0.00% -29.15% -7.62% -12.07% -20.12% -5.86%
Return On Investment Capital (ROIC_SIMPLE)		 - - -0.48% -44.41% -16.29% -23.12%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 53,367.71% 19.00% 267.09% 154.61% 472.62%
R&D to Revenue		 0.00% 278,138.80% 84.47% 1,131.47% 332.30% 630.28%
Operating Expenses to Revenue		 0.00% 331,506.51% 103.46% 1,398.56% 486.91% 1,102.90%
Earnings before Interest and Taxes (EBIT)		 -6.63 -32 -30 -188 -258 -231
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.63 -32 -30 -188 -259 -233
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 3.16 3.13 5.82
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 3.16 3.14 5.82
Price to Revenue (P/Rev)		 0.00 0.00 0.00 64.66 52.11 176.77
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 40.49 33.80 144.32
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.06 -0.92 -1.00 -1.12 -1.09
Leverage Ratio		 0.00 1.20 1.11 1.14 1.16 1.13
Compound Leverage Factor		 0.00 1.21 0.83 1.07 1.08 1.00
Debt to Total Capital		 0.00% 0.22% 0.01% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.22% 0.01% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 99.78% 99.99% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 1.87 15.60 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.01 -0.02 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 2.54 188.39 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.01 -0.02 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 7.31 12.51 26.37
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.00 5.96 12.64 6.95 8.08 7.88
Quick Ratio		 0.00 5.96 12.64 6.82 7.80 7.42
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -20 -55 -27 -99 -188
Operating Cash Flow to CapEx		 0.00% -125,820.00% 4,825.79% -588,408.33% -23,595.83% -60,074.39%
Free Cash Flow to Firm to Interest Expense		 0.00 -81.89 -192.93 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -17.32 -116.50 37.16 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -17.32 -116.59 36.39 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.32 0.03 0.08 0.03
Accounts Receivable Turnover		 0.00 0.00 12.21 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.05 556.47 140.86 316.41 72.01
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 234,496.84 29.90 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 234,496.84 29.90 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 -3.61 49 -52 -77 -47
Invested Capital Turnover		 0.00 -0.01 4.50 -10.11 -0.71 -0.36
Increase / (Decrease) in Invested Capital		 0.00 -3.61 53 -101 -25 30
Enterprise Value (EV)		 0.00 0.00 0.00 571 1,540 3,248
Market Capitalization		 0.00 0.00 0.00 911 2,374 3,978
Book Value per Share		 $0.00 $0.00 $6.36 $3.54 $8.20 $6.03
Tangible Book Value per Share		 $0.00 $0.00 $5.26 $3.53 $8.19 $6.02
Total Capital		 0.00 56 518 288 758 683
Total Debt		 0.00 0.13 0.06 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.13 0.06 0.00 0.00 0.00
Net Debt		 0.00 -60 -469 -340 -834 -730
Capital Expenditures (CapEx)		 0.00 0.02 0.22 0.02 0.67 0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.64 -28 -44 -78 -48
Debt-free Net Working Capital (DFNWC)		 0.00 55 441 297 756 590
Net Working Capital (NWC)		 0.00 55 441 297 756 590
Net Nonoperating Expense (NNE)		 2.38 8.74 20 49 118 46
Net Nonoperating Obligations (NNO)		 0.00 -60 -469 -340 -834 -730
Total Depreciation and Amortization (D&A)		 0.00 0.02 0.01 0.05 -0.11 -1.19
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -45,534.23% -26.93% -309.13% -170.52% -211.75%
Debt-free Net Working Capital to Revenue		 0.00% 544,388.46% 429.90% 2,107.13% 1,660.33% 2,621.49%
Net Working Capital to Revenue		 0.00% 544,388.46% 429.90% 2,107.13% 1,660.33% 2,621.49%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($2.15) ($2.56) ($1.72)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 89.27M 109.82M 114.98M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.15) ($2.56) ($1.72)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 89.27M 109.82M 114.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 89.27M 109.82M 114.98M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.64 -24 -2.49 -128 -123 -158
Normalized NOPAT Margin		 0.00% -231,984.56% -2.42% -908.99% -270.84% -702.03%
Pre Tax Income Margin		 0.00% -317,772.91% -22.04% -1,255.57% -530.25% -905.74%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -15.78 -131.40 -104.82 0.00 0.00 0.00
NOPAT to Interest Expense		 -11.05 -96.66 -8.68 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -15.78 -131.50 -105.59 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -11.05 -96.75 -9.45 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -0.22% -0.78%

Quarterly Metrics And Ratios for NewAmsterdam Pharma

This table displays calculated financial ratios and metrics derived from NewAmsterdam Pharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 114,975,422.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 114,975,422.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.42
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -83.76% 32.73% 889.83% 1,490.54% 112.56% 740.06% -98.80% -99.75% 2.08%
EBITDA Growth		 0.00% 0.00% -125.45% -2.25% 58.02% -85.35% 51.11% 43.35% -275.30% 15.98% -14.11%
EBIT Growth		 0.00% 0.00% -125.44% -2.27% 57.98% -85.40% 51.60% 44.35% -273.23% 15.79% -15.39%
NOPAT Growth		 0.00% 0.00% -39.22% -23.76% 49.55% 15.36% -24.23% 32.22% -120.55% -52.63% 15.24%
Net Income Growth		 0.00% 0.00% -123.16% -1.87% 64.68% -86.24% 57.85% 55.48% -332.54% 18.72% -22.55%
EPS Growth		 0.00% 0.00% -107.84% 12.77% 68.42% -51.67% 67.92% 63.41% -238.89% 31.87% -17.65%
Operating Cash Flow Growth		 0.00% 0.00% -71.36% -84.20% 73.39% -13.32% 33.21% 30.21% -162.11% -9.06% 16.08%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -383.47% -1,080.07% -301.75% -1,252.98% 66.99%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -47.32% 55.13% 88.82% 33.26% 39.05% -39.67%
Revenue Q/Q Growth		 71.29% -72.70% 0.00% 62.67% 1,177.36% -56.13% -76.68% 542.88% -98.18% -90.80% 9,400.00%
EBITDA Q/Q Growth		 -16.99% -3.88% 0.00% 54.71% 51.97% -358.68% 51.00% 47.51% -218.16% -2.93% 33.61%
EBIT Q/Q Growth		 -16.99% -3.87% 0.00% 54.70% 51.93% -358.31% 51.50% 47.91% -222.36% -3.40% 33.55%
NOPAT Q/Q Growth		 -16.66% -3.06% 0.00% 5.24% 52.44% -72.90% -59.44% 48.30% -54.74% -19.65% 11.46%
Net Income Q/Q Growth		 -23.09% -5.01% 0.00% 58.40% 57.32% -453.72% 57.12% 56.07% -314.68% -4.05% 35.35%
EPS Q/Q Growth		 -21.28% -5.26% 0.00% 61.32% 56.10% -405.56% 62.64% 55.88% -306.67% -1.64% 35.48%
Operating Cash Flow Q/Q Growth		 -60.30% 29.59% 0.00% 1.14% 76.84% -199.80% 2.70% -3.30% 13.01% -24.74% 25.13%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -78.80% 307.72% -121.34% -1,436.75% 26.71% 16.07% -43.13% 62.50%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 37.60% -1.38% -74.82% 59.43% 84.45% -505.23% -59.66% 7.02%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,706.15% -6,491.03% -6,911.85% -1,924.44% -72.35% -756.43% -1,589.62% -129.78% -22,715.23% -254,256.25% -1,776.94%
Operating Margin		 -1,685.07% -6,360.40% -3,960.17% -2,306.93% -85.89% -338.47% -2,314.47% -186.13% -15,845.69% -206,187.50% -1,921.71%
EBIT Margin		 -1,706.63% -6,492.65% -6,912.92% -1,925.27% -72.45% -756.83% -1,574.14% -127.55% -22,619.83% -254,365.63% -1,779.31%
Profit (Net Income) Margin		 -1,602.62% -6,163.76% -6,692.86% -1,711.58% -57.18% -721.71% -1,327.30% -90.70% -20,691.09% -234,134.38% -1,593.45%
Tax Burden Percent		 100.00% 100.05% 100.00% 100.00% 99.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.91% 94.88% 96.82% 88.90% 78.93% 95.36% 84.32% 71.11% 91.47% 92.05% 89.55%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -43.87% -55.53% -59.21% -52.50% -46.20% -31.51% -28.43% -39.94% -28.29% -29.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -199.79% -97.11% -32.00% -5.54% -56.92% -113.56% -12.94% -1,300.88% -7,006.52% -51.77%
Return on Assets (ROA)		 0.00% -189.67% -94.02% -28.45% -4.37% -54.28% -95.75% -9.20% -1,189.96% -6,449.25% -46.36%
Return on Common Equity (ROCE)		 0.00% -43.87% -55.53% -59.21% -52.50% -46.20% -31.51% -28.43% -39.94% -28.29% -29.49%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -55.53% -59.21% -52.50% 0.00% -24.10% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -35 -36 -39 -37 -18 -30 -48 -25 -39 -46 -41
NOPAT Margin		 -1,179.55% -4,452.28% -2,772.12% -1,614.85% -60.12% -236.93% -1,620.13% -130.29% -11,091.98% -144,331.25% -1,345.20%
Net Nonoperating Expense Percent (NNEP)		 0.00% -4.04% -22.83% -1.02% 0.40% -10.54% 1.35% 1.25% -5.66% -3.67% -0.99%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.40% - - - -3.99% -6.21% -3.20% -5.30% -6.76% -6.15%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 310.37% 1,318.18% 1,031.62% 722.90% 63.25% 165.25% 911.75% 142.41% 7,045.98% 85,681.25% 771.41%
R&D to Revenue		 1,474.70% 5,142.22% 3,028.55% 1,684.03% 122.64% 273.21% 1,502.72% 143.72% 8,899.71% 120,606.25% 1,250.30%
Operating Expenses to Revenue		 1,785.07% 6,460.40% 4,060.17% 2,406.93% 185.89% 438.47% 2,414.47% 286.13% 15,945.98% 206,284.38% 2,021.71%
Earnings before Interest and Taxes (EBIT)		 -50 -52 -97 -44 -21 -97 -47 -24 -79 -81 -54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -50 -52 -97 -44 -21 -97 -47 -25 -79 -81 -54
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 3.16 4.68 4.46 3.94 3.13 2.89 2.61 4.40 5.82 5.53
Price to Tangible Book Value (P/TBV)		 0.00 3.16 4.69 4.47 3.95 3.14 2.89 2.61 4.40 5.82 5.54
Price to Revenue (P/Rev)		 0.00 64.66 281.10 232.82 44.48 52.11 47.69 31.77 90.89 176.77 163.10
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 40.49 210.98 174.80 31.90 33.80 30.54 19.53 69.40 144.32 131.69
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.18 -1.17 -1.11 -1.12 -1.12 -1.08 -1.04 -1.07 -1.09 -1.05
Leverage Ratio		 0.00 1.14 1.19 1.15 1.16 1.16 1.10 1.08 1.11 1.13 1.08
Compound Leverage Factor		 0.00 1.08 1.15 1.03 0.92 1.10 0.93 0.77 1.01 1.04 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 8.60 14.33 16.86 14.38 13.13 32.84 33.32 32.45 27.01 31.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 6.95 8.17 9.83 10.61 8.08 19.98 21.08 12.57 7.88 9.76
Quick Ratio		 0.00 6.82 8.06 9.51 10.25 7.80 19.76 20.24 12.06 7.42 9.43
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 31 6.47 26 -5.63 -86 -63 -53 -76 -29
Operating Cash Flow to CapEx		 -521,955.56% -1,102,466.67% -14,182.34% -25,827.27% -16,669.33% -1,249,366.67% -227,925.00% -42,807.95% -78,021.43% -40,875.00% -80,536.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.03 0.01 0.02 0.08 0.08 0.07 0.10 0.06 0.03 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 140.86 67.94 31.73 145.43 316.41 278.11 234.45 127.23 72.01 73.14
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -52 -69 -43 -44 -77 -31 -4.84 -29 -47 -43
Invested Capital Turnover		 0.00 -0.27 -0.20 -0.34 -1.53 -0.71 -0.94 -2.66 -0.96 -0.36 -0.61
Increase / (Decrease) in Invested Capital		 0.00 0.00 -69 -43 -44 -25 38 38 15 30 -12
Enterprise Value (EV)		 0.00 571 1,448 1,298 1,072 1,540 1,439 1,250 2,446 3,248 2,972
Market Capitalization		 754 911 1,929 1,728 1,494 2,374 2,248 2,033 3,203 3,978 3,680
Book Value per Share		 $0.00 $3.54 $4.58 $4.31 $4.21 $8.20 $7.08 $6.93 $6.46 $6.03 $5.79
Tangible Book Value per Share		 $0.00 $3.53 $4.57 $4.30 $4.20 $8.19 $7.07 $6.93 $6.46 $6.02 $5.78
Total Capital		 0.00 288 412 387 379 758 777 778 728 683 665
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -340 -481 -431 -423 -834 -808 -783 -757 -730 -709
Capital Expenditures (CapEx)		 0.01 0.00 0.39 0.21 0.08 0.00 0.02 0.09 0.04 0.10 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -44 -53 -31 -26 -78 -32 -5.82 -30 -48 -47
Debt-free Net Working Capital (DFNWC)		 0.00 297 428 400 397 756 776 733 674 590 591
Net Working Capital (NWC)		 0.00 297 428 400 397 756 776 733 674 590 591
Net Nonoperating Expense (NNE)		 12 14 55 2.20 -0.86 62 -8.72 -7.58 33 29 7.55
Net Nonoperating Obligations (NNO)		 0.00 -340 -481 -431 -423 -834 -808 -783 -757 -730 -709
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.02 0.02 0.03 0.05 -0.46 -0.43 -0.33 0.04 0.07
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -309.13% -773.11% -413.03% -77.72% -170.52% -68.07% -9.10% -85.69% -211.75% -207.48%
Debt-free Net Working Capital to Revenue		 0.00% 2,107.13% 6,238.65% 5,388.54% 1,180.62% 1,660.33% 1,646.99% 1,145.73% 1,912.60% 2,621.49% 2,617.43%
Net Working Capital to Revenue		 0.00% 2,107.13% 6,238.65% 5,388.54% 1,180.62% 1,660.33% 1,646.99% 1,145.73% 1,912.60% 2,621.49% 2,617.43%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.60) ($1.06) ($0.41) ($0.18) ($0.91) ($0.34) ($0.15) ($0.61) ($0.62) ($0.40)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M 112.63M 113.39M 114.98M 116.90M
Adjusted Diluted Earnings per Share		 $0.00 ($0.60) ($1.06) ($0.41) ($0.18) ($0.91) ($0.34) ($0.15) ($0.61) ($0.62) ($0.40)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M 112.63M 113.39M 114.98M 116.90M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M 112.63M 113.39M 114.98M 116.90M
Normalized Net Operating Profit after Tax (NOPAT)		 -35 -36 -39 -37 -18 -30 -48 -25 -39 -46 -41
Normalized NOPAT Margin		 -1,179.55% -4,452.28% -2,772.12% -1,614.85% -60.12% -236.93% -1,620.13% -130.29% -11,091.78% -144,331.25% -1,345.20%
Pre Tax Income Margin		 -1,602.62% -6,160.40% -6,692.86% -1,711.58% -57.19% -721.71% -1,327.30% -90.70% -20,691.09% -234,134.38% -1,593.45%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.22% -0.86% -0.97% -0.73% -0.78% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, data-driven read on NewAmsterdam Pharma Co N.V. (NAMS) across the last four years, focusing on trends in the income statement, cash flow, and balance sheet from quarterly statements.

  • Substantial liquidity: Cash & equivalents remained in the hundreds of millions through 2025 (about $748.4M at 2025-Q1 and roughly $538.4M by 2025-Q3), providing a solid runway for ongoing development and operating needs.
  • Financing activity provides periodic liquidity: Net cash from financing activities was positive in multiple 2025 quarters, contributing to overall liquidity beyond daily operating cash flow.
  • Modest cash inflow from continuing investing activities in 2025-Q3: Net cash from continuing investing activities was about $2.5M in Q3 2025, indicating a relatively conservative investing pace at that point.
  • Robust equity base: Total equity around $0.73B in 2025-Q3 (Total Common Equity near $728.07M), suggesting a solid capitalization framework to support near-term funding needs if milestones require it.
  • Asset base vs. liabilities: Total assets hover near $0.8B in 2025, with total liabilities in the low tens of millions (e.g., ~$58.4M at 2025-Q3), indicating a favorable asset-to-liability balance on a quarterly view.
  • Revenue remains very small and volatile: Example quarterly operating revenue ranges from a few thousand to a few hundred thousand, with quarterly results heavily skewed by R&D spending rather than product sales (e.g., Q4 2025 revenue $32k vs. Q3 2025 revenue $348k and Q2 2025 revenue $19.1M).
  • No obvious large debt burden: Liabilities are modest relative to equity, suggesting limited near-term debt maturities visible in the quarterly data and a stronger equity cushion to absorb losses or fund milestones.
  • Net income consistently negative: The company recorded net income (loss) of about -$74.9M in 2025-Q4 and -$72.0M in 2025-Q3, reflecting ongoing losses typical of a clinical-stage biotech before commercial products.
  • Operating cash flow burn persists: Net cash from continuing operating activities was negative in each 2025 quarter (e.g., around -$40.9M in 2025-Q4 and -$32.8M in 2025-Q3), indicating ongoing cash burn from core operations.
  • High current expense base relative to revenue: Total operating expenses remained substantial (e.g., 2025-Q4 total operating expenses around $66.0M) despite minimal operating revenue, underscoring the burn rate required to fund development milestones.
05/15/26 04:34 AM ETAI Generated. May Contain Errors.

NewAmsterdam Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NewAmsterdam Pharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

NewAmsterdam Pharma's net income appears to be on an upward trend, with a most recent value of -$203.82 million in 2025, rising from -$7.02 million in 2020. The previous period was -$241.60 million in 2024.

NewAmsterdam Pharma's total operating income in 2025 was -$225.68 million, based on the following breakdown:
  • Total Gross Profit: $22.50 million
  • Total Operating Expenses: $248.19 million

Over the last 5 years, NewAmsterdam Pharma's total revenue changed from $0.00 in 2020 to $22.50 million in 2025, a change of 2,250,300,000.0%.

NewAmsterdam Pharma's total liabilities were at $85.85 million at the end of 2025, a 19.9% decrease from 2024, and a 659.2% increase since 2021.

In the past 4 years, NewAmsterdam Pharma's cash and equivalents has ranged from $60.09 million in 2021 to $771.74 million in 2024, and is currently $490.00 million as of their latest financial filing in 2025.

Over the last 5 years, NewAmsterdam Pharma's book value per share changed from 0.00 in 2020 to 6.03 in 2025, a change of 602.7%.


Related Companies

Financial statements for NASDAQ:NAMSW last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel